QT Imaging Holdings (QTI) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $1.7M, up from $3K in Q2 2023, driven by sales of four breast scanners and marking the first full quarter as a public company.

• Net loss attributable to common stockholders for Q2 2024 was $6.4M, compared to $1.3M in Q2 2023.

• The company completed a business combination with GigCapital5 in March 2024, resulting in significant non-recurring transaction expenses.

• Exclusive U.S. distribution agreement signed with NXC Imaging in June 2024 to drive future sales.

• Advanced engineering and clinical feasibility studies with strategic partners and announced new partnerships with leading cancer centers.

Financial highlights

• Six-month revenue ended June 30, 2024 was $3.1M, up from $10.7K year-over-year.

• Gross profit for the six months was $1.6M, compared to a gross loss of $39K in the prior year.

• Operating expenses for the six months rose to $9.4M from $2.9M, mainly due to $3.9M in non-recurring transaction costs.

• Net loss for the six months was $10.7M, including a $5.2M deemed dividend from warrant modification.

• Cash and equivalents at June 30, 2024 was $4.6M, up from $185K at year-end 2023.

Outlook and guidance

• Management expects continued losses and negative cash flows as commercialization and R&D investments continue.

• Expects to maintain revenue delivery pace in the second half of 2024, with higher gross margin anticipated due to inventory cost structure.

• Additional capital may be needed if revenue growth does not meet expectations.

• The Standby Equity Purchase Agreement provides access to up to $40M in additional capital.

• 2024 is positioned as a transitional year focused on commercialization and strategic partnerships.